C Fan, Z Jiang, C Teng, X Song, L Li, W Shen, Q Jiang, D Huang, Y Lv, L Du, G Wang, Y Hu, S Man, Z Zhang, N Gao, F Wang, T Shi, T Xin
BACKGROUND: This study aimed to evaluate the efficacy and safety of intrathecal pemetrexed (IP) for treating patients with leptomeningeal metastases (LM) from non-small-cell lung cancer (NSCLC) who progressed from epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) treatment in an expanded, prospective, single-arm, phase II clinical study (ChiCTR1800016615). PATIENTS AND METHODS: Patients with confirmed NSCLC-LM who progressed from TKI received IP (50 mg, day 1/day 5 for 1 week, then every 3 weeks for four cycles, and then once monthly) until disease progression or intolerance...
February 19, 2024: ESMO Open